The FDA approval is based on the STARS-ADHD-Adult study, which involved 221 patients with combined or inattentive subtype ADHD who used EndeavorOTC at home for six weeks on a mobile device.

Unlocking the adult market for EndeavorRx could dramatically expand the eligible patient population for the DTx, particularly as there has been an explosion in diagnosis of ADHD in adults over the ...

The clinical efficacy of atomoxetine in the treatment of ADHD has been evaluated in six published clinical trials of children and adolescents and two studies enrolling only adults. Clinical trial ...